Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 64 for “"Engineered T cells"”.

  1. PHARMACOLOGICAL COSTIMULATION OF ENGINEERED T CELLS

    … targeting synthetic receptor on a patient’s T cells. While endogenous T cells rely on costimulatory signals for their development but not their effector function, CAR T cells are completely reliant on costimulatory domains incorporated within the CAR structure to promote T cell expansion and …

    mcmaster Repository record for PHARMACOLOGICAL COSTIMULATION OF ENGINEERED T CELLS (opens in a new tab)

  2. TARGETING PATHOGENIC FIBROBLASTS WITH ENGINEERED T CELLS

    … by substantial alterations to constituent cells. Fibroblasts are mesenchymal cells of particular interest within the diseased heart because they contribute to pathogenic fibrosis (stiffening of the matrix) and serve as pro-inflammatory signaling hubs. Following injury fibroblasts …

    penn Repository record for TARGETING PATHOGENIC FIBROBLASTS WITH ENGINEERED T CELLS (opens in a new tab)

  3. Development of BCMA-specific engineered T cells targeting multiple myeloma

    … the endogenous T cell receptor and allows T cells to autoregulate their activity. Our experience in solid tumor models has shown that TAC-T cells are similarly efficacious and significantly less toxic than CAR-T cells. This thesis describes our optimization of BCMA-specific TAC-T cells and …

    mcmaster Repository record for Development of BCMA-specific engineered T cells targeting multiple myeloma (opens in a new tab)

  4. Sensitivity tuning of TCR-engineered T-cells using CD8 co-receptor variants

    TCR-engineered T-cells are a promising tool for the treatment of haematological and solid malignancies. The key to the success of T-cell therapy lies in the discovery of high affinity TCRs that target tumour cells, while leaving healthy tissues intact. However, the majority of tumour-targeting TCRs …

    bristol Repository record for Sensitivity tuning of TCR-engineered T-cells using CD8 co-receptor variants (opens in a new tab) Download PDF for Sensitivity tuning of TCR-engineered T-cells using CD8 co-receptor variants (opens in a new tab)

  5. Augmentation of anti-myeloma engineered T cells by pharmacological or genetic interventions

    … cancers, including multiple myeloma. T cells possess robust anti-tumor functions which can be harnessed and refined for the treatment of cancers. Genetic engineering of T cells to express a chimeric antigen receptor (CAR) confers antigen-specific tumor-targeting, and adoptive transfer of …

    mcmaster Repository record for Augmentation of anti-myeloma engineered T cells by pharmacological or genetic interventions (opens in a new tab)

  6. Characterizing the Response of TAC- and CAR-Engineered T cells Following Antigenic Stimulation

    T lymphocytes engineered with chimeric antigen receptors (CARs) have shown remarkable success in the treatment of leukemias. Conventional CARs seek to recapitulate TCR and costimulatory signals through fusion of T cell signaling elements into a single receptor. The robust anti-tumor activity of CAR …

    mcmaster Repository record for Characterizing the Response of TAC- and CAR-Engineered T cells Following Antigenic Stimulation (opens in a new tab)

  7. IFNγ IS REQUIRED FOR OPTIMAL THERAPEUTIC EFFICACY OF KIR-CAR ENGINEERED T CELLS

    … important role in the anti-tumor function of T cells and is also a significant contributor to adaptive resistance. Here, we investigated the contribution of IFNγ to the anti-tumor function of T cells engineered with synthetic antigen receptor based on KIR2DS2 (KIR-CARs). We generated IFNγ …

    mcmaster Repository record for IFNγ IS REQUIRED FOR OPTIMAL THERAPEUTIC EFFICACY OF KIR-CAR ENGINEERED T CELLS (opens in a new tab)

  8. ASYMMETRIC CELL DIVISION AS A MECHANISM OF FATE INDUCTION IN GENETICALLY ENGINEERED T CELLS

    … and chimeric autoantibody receptor (CAAR) T cells are novel cellular immunotherapy strategies that have recently entered clinical practice for the treatment of malignancies and autoimmune diseases. Early expansion and long-term persistence of these genetically engineered T cells predict …

    penn Repository record for ASYMMETRIC CELL DIVISION AS A MECHANISM OF FATE INDUCTION IN GENETICALLY ENGINEERED T CELLS (opens in a new tab)

  9. Targeting of B-cell malignancy using novel parallel chimeric antigen receptor (pCAR) engineered T-cells

    … chimeric co-stimulatory receptor (CCR), were engineered. The hypothesis underlying pCAR design is that optimal dual-costimulation requires positioning of endodomains<i> in trans</i> and proximal to the membrane which will, in turn, improve CAR T-cell efficacy. To investigate this premise, …

    kings Repository record for Targeting of B-cell malignancy using novel parallel chimeric antigen receptor (pCAR) engineered T-cells (opens in a new tab) Download PDF for Targeting of B-cell malignancy using novel parallel chimeric antigen receptor (pCAR) engineered T-cells (opens in a new tab)

  10. Development of novel chimeric receptors for delivery of costimulation to tumor-reactive engineered T cells

    … success and promise. Adoptive transfer of T cells engineered for tumor reactivity is an avenue of therapy for patients with previously untreatable disease. Our lab has developed a novel chimeric receptor, called a T cell antigen coupler (TAC), which redirects T cell cytotoxicity towards a …

    mcmaster Repository record for Development of novel chimeric receptors for delivery of costimulation to tumor-reactive engineered T cells (opens in a new tab)

  11. Modulation of CAR-LCK engagement to augment the anti-tumor function of genetically engineered T-cells

    … with chimeric antigen receptor (CAR)-T cells has dramatically altered the landscape of cancer therapy. However, despite impressive clinical responses and high rates of complete remission observed in B-cell acute lymphoblastic leukemia, lymphomas and multiple myeloma, there is still a …

    wurz-thes Repository record for Modulation of CAR-LCK engagement to augment the anti-tumor function of genetically engineered T-cells (opens in a new tab)

  12. Exploring the therapeutic potential of CAR-engineered T-cells targeting endothelial markers on tumour and inflamed vasculature

    T-cells engineered to target tumour antigens through surface-expressed chimeric antigen receptors (CARs) are highly effective in treating some leukaemias. The challenge is to extend this success to solid tumours. Tumour endothelial marker 8 (TEM8) is a conserved transmembrane protein overexpressed …

    birmingham Download PDF for Exploring the therapeutic potential of CAR-engineered T-cells targeting endothelial markers on tumour and inflamed vasculature (opens in a new tab)

  13. Cd56-Specific T Cells: Using Genetically Engineered T Cells to Redirect Specificity to A T Cell Expressed Antigen

    … for applying CARs to new targets. Using T cells to target a T cell expressed antigen, such as CD56, seems counterintuitive in that the T cells would be susceptible to self-targeting a.k.a. fratricide. However, we expand CD56-specific CAR+ T cells that co-express the CD56 antigen. Since …

    uthsc Repository record for Cd56-Specific T Cells: Using Genetically Engineered T Cells to Redirect Specificity to A T Cell Expressed Antigen (opens in a new tab)

  14. DEVELOPING A HIGH THROUGHPUT ASSAY TO INVESTIGATE CHEMICAL AGENTS WHICH SENSITIZE TUMOUR CELLS TO KILLING BY CAR ENGINEERED T CELLS

    … established that infusion of tumour-specific T cells can cause regression of advanced tumours and prevent tumour relapse. While tumour-specific T cells are typically rare, engineering methods have been developed to introduce tumour-specific receptors into T cells and engender peripheral blood T …

    mcmaster Repository record for DEVELOPING A HIGH THROUGHPUT ASSAY TO INVESTIGATE CHEMICAL AGENTS WHICH SENSITIZE TUMOUR CELLS TO KILLING BY CAR ENGINEERED T CELLS (opens in a new tab)

  15. Metabolic and Immune Cell Therapies in Combination with Radiotherapy for the Treatment of Non-Small Cell Lung Cancer

    … growth factor receptor 2 (HER2)-targeted engineered T cells, in combination with radiotherapy for the treatment of NSCLC. It also aims to delineate the mechanisms by which these therapies exert their effects. We first demonstrate that canagliflozin, a drug originally approved for treating …

    mcmaster Repository record for Metabolic and Immune Cell Therapies in Combination with Radiotherapy for the Treatment of Non-Small Cell Lung Cancer (opens in a new tab)

  16. Revolutionizing T cell Therapy for Pancreatic Cancer: Harnessing the Power of T cell Receptor Exchange Mice

    … The adoptive transfer of T cell receptor (TCR) engineered T cells specific to mesothelin (Msln) can effectively target PDA, but efficacy is limited by the suppressive TME that promotes engineered T cell dysfunction. T cell receptor (TCR) transgenic mice represent an invaluable tool to study …

    umn Repository record for Revolutionizing T cell Therapy for Pancreatic Cancer: Harnessing the Power of T cell Receptor Exchange Mice (opens in a new tab)

  17. Elucidating T cell characteristics that enable optimal control of HIV replication

    … an individual undergoes an HIV cure regimen. T cells are ideally suited to serve in this role, but given the state of the HIV-specific T cell response, it is unclear how to best restore HIV-specific T cell activity. To compare the efficacy of TCR and CAR T cell strategies we generated engineered …

    penn Repository record for Elucidating T cell characteristics that enable optimal control of HIV replication (opens in a new tab)

  18. Combining CAR-T cells and Oncolytic Viruses for Cancer Immunotherapy

    … While the use of chimeric antigen receptor (CAR)-engineered T cells has shown dramatic clinical benefit for use in blood-based cancers, solid tumors remain a significant hurdle. METHODS: We have investigated the use of multi-faceted immunotherapies combining CAR-T cells with oncolytic virotherapy. …

    mcmaster Repository record for Combining CAR-T cells and Oncolytic Viruses for Cancer Immunotherapy (opens in a new tab)

  19. Engineering Cd8+ T Cells To Overcome Death Signaling Within The Tumor Microenvironment

    Adoptive cell transfer (ACT) using genetically-engineered or tumor infiltrating T cells can have efficacy in patients with metastatic cancers, but the efficacy of ACT may be limited by the ability of T cells to expand and persist following transfer. T cells harvested from blood or tumor for ACT are …

    penn Repository record for Engineering Cd8+ T Cells To Overcome Death Signaling Within The Tumor Microenvironment (opens in a new tab)

  20. Remote control of CAR T cell therapies by thermal targeting

    … emerging class of cellular therapies based on T cells. As the use of these 'living drugs' grows, scientists, engineers, and clinicians continue to improve their therapeutic and safety profiles by developing new mechanisms to control immune cell activity in the body. Currently, the limited ability …

    gatech Repository record for Remote control of CAR T cell therapies by thermal targeting (opens in a new tab)

Page 1 of 4